Published in J Cell Mol Med on May 07, 2008
Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer (2011) 1.59
Sorafenib: where do we go from here? Hepatology (2010) 1.38
Hepatocellular carcinoma: insight from animal models. Nat Rev Gastroenterol Hepatol (2011) 1.28
Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. Therap Adv Gastroenterol (2010) 1.10
In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model. Neoplasia (2009) 1.09
Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition. Liver Cancer (2012) 0.98
Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma - systematic review and meta-analysis. Cancer Med (2013) 0.91
Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. Ann Oncol (2013) 0.91
Autophagy modulation as a potential therapeutic target for liver diseases. J Clin Exp Hepatol (2014) 0.87
Angiogenesis: multiple masks in hepatocellular carcinoma and liver regeneration. Hepatol Int (2010) 0.84
Targeted therapies in the treatment of advanced hepatocellular carcinoma. Clin Med Insights Oncol (2013) 0.83
Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development. Oncotarget (2015) 0.82
Targeted therapy in hepatocellular carcinoma. Int J Hepatol (2011) 0.82
Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: a case report. World J Gastroenterol (2010) 0.81
mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma. Br J Cancer (2015) 0.81
Medical treatment of unresectable hepatocellular carcinoma: Going beyond sorafenib. World J Hepatol (2010) 0.80
Glo1 genetic amplification as a potential therapeutic target in hepatocellular carcinoma. Int J Clin Exp Pathol (2014) 0.80
The Role of Autophagy in Hepatocellular Carcinoma. Int J Mol Sci (2015) 0.77
Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response. BMC Cancer (2015) 0.77
Accomplishments in 2008 in the management of hepatobiliary cancers. Gastrointest Cancer Res (2009) 0.76
Evaluation of the impact of the cancer therapy everolimus on the central nervous system in mice. PLoS One (2014) 0.76
Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma. Invest New Drugs (2015) 0.76
In vivo photoacoustic tomography of EGFR overexpressed in hepatocellular carcinoma mouse xenograft. Photoacoustics (2016) 0.75
Optimization of immunosuppressive medication upon liver transplantation against HCC recurrence. Transl Gastroenterol Hepatol (2016) 0.75
The androgen receptor as an emerging target in hepatocellular carcinoma. J Hepatocell Carcinoma (2015) 0.75
Differential Antitumoral Properties and Renal-Associated Tissue Damage Induced by Tacrolimus and Mammalian Target of Rapamycin Inhibitors in Hepatocarcinoma: In Vitro and In Vivo Studies. PLoS One (2016) 0.75
Potentiation of the anticancer effects of everolimus using a dual mTORC1/2 inhibitor in hepatocellular carcinoma cells. Oncotarget (2016) 0.75
Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy. Diseases (2015) 0.75
The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 28.11
Hepatocellular carcinoma. Lancet (2003) 22.54
Upstream and downstream of mTOR. Genes Dev (2004) 21.61
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med (2004) 13.57
mTOR and cancer: insights into a complex relationship. Nat Rev Cancer (2006) 11.86
The TOR pathway: a target for cancer therapy. Nat Rev Cancer (2004) 9.02
Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene (2004) 7.92
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res (2005) 7.34
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med (2002) 7.06
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol (2006) 6.95
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res (2006) 6.66
Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer (2004) 6.07
Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J (1999) 4.80
Contributions of human tumor xenografts to anticancer drug development. Cancer Res (2006) 4.72
Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell (2006) 4.33
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene (2005) 4.07
Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med (2003) 3.61
The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell (2005) 3.59
Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res (2000) 3.14
mTOR and cancer therapy. Oncogene (2006) 3.07
Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem (2002) 2.95
SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation (1997) 2.80
A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst (2005) 2.73
Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res (2004) 2.64
Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br J Cancer (1984) 2.55
Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res (2004) 2.44
Recurrence of hepatocellular carcinoma after surgery. Br J Surg (1996) 2.27
Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol (2003) 2.24
mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res (2004) 2.14
Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years. Ann Surg (1993) 2.06
New therapies for hepatocellular carcinoma. Oncogene (2006) 2.05
Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist (2006) 2.05
Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int (2003) 1.83
Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci U S A (2004) 1.82
Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol (2007) 1.63
Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol (2007) 1.56
Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol (2003) 1.55
Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol (2005) 1.45
Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation (2002) 1.33
The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci U S A (2000) 1.27
Regulation of hepatitis B virus replication by the phosphatidylinositol 3-kinase-akt signal transduction pathway. J Virol (2007) 1.10
CCI-779 Wyeth. Curr Opin Investig Drugs (2002) 1.08
Xenografts of human hepatocellular carcinoma: a useful model for testing drugs. Clin Cancer Res (2006) 1.07
p21-activated kinase 1 is activated through the mammalian target of rapamycin/p70 S6 kinase pathway and regulates the replication of hepatitis C virus in human hepatoma cells. J Biol Chem (2007) 1.05
RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer. Cancer Res (2005) 0.96
Complete remission of postransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil. Transplantation (2005) 0.85
Successful use of sirolimus in a patient with bulky ovarian metastasis of hepatocellular carcinoma after liver transplantation. Transplant Proc (2005) 0.81
Hepatocyte growth factor stimulates the growth and activates mitogen-activated protein kinase in human hepatoma cells. J Biomed Sci (1998) 0.79
The journal impact factor: too much of an impact? Ann Acad Med Singapore (2006) 2.98
Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology (2011) 2.36
Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet (2013) 2.15
Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol Cancer Ther (2007) 2.01
Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genet (2009) 1.96
Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Hepatol (2008) 1.87
The effect of photodynamic therapy on tumor angiogenesis. Cell Mol Life Sci (2009) 1.62
A combined comparative genomic hybridization and expression microarray analysis of gastric cancer reveals novel molecular subtypes. Cancer Res (2003) 1.60
Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res (2008) 1.57
Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut (2011) 1.56
Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol (2003) 1.55
Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol (2009) 1.51
Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. Cancer Res (2011) 1.49
Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res (2004) 1.47
Postoperative endocrine function in patients with surgically treated thyrotoxicosis. Head Neck (2004) 1.42
General Surgery (GS) Residency Selection Process: A Comparison Between Singapore (Singhealth) and United States. Ann Acad Med Singapore (2014) 1.38
Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Cell Mol Med (2009) 1.30
Nanoparticles in photodynamic therapy. Chem Rev (2015) 1.26
Aspirin as adjuvant therapy for colorectal cancer--reinterpreting paradigms. Nat Rev Clin Oncol (2012) 1.26
Analysis of prognostic factors of comprehensive geriatric assessment and development of a clinical scoring system in elderly Asian patients with cancer. J Clin Oncol (2011) 1.24
MicroRNA-224 is up-regulated in hepatocellular carcinoma through epigenetic mechanisms. FASEB J (2012) 1.24
Epstein-Barr virus-associated smooth muscle tumors are distinctive mesenchymal tumors reflecting multiple infection events: a clinicopathologic and molecular analysis of 29 tumors from 19 patients. Am J Surg Pathol (2006) 1.20
AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). J Hepatol (2009) 1.12
Retroperitoneal liposarcomas: the experience of a tertiary Asian center. World J Surg Oncol (2011) 1.10
Xenografts of human hepatocellular carcinoma: a useful model for testing drugs. Clin Cancer Res (2006) 1.07
Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor. Mol Cancer Ther (2009) 1.07
Head & neck optical diagnostics: vision of the future of surgery. Head Neck Oncol (2009) 1.05
Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a Phase II trial using a triplet combination. Cancer (2005) 1.05
Quercetin-induced growth inhibition and cell death in nasopharyngeal carcinoma cells are associated with increase in Bad and hypophosphorylated retinoblastoma expressions. Oncol Rep (2004) 1.04
Primary malignant melanoma of the esophagus with multiple esophageal lesions. Nat Clin Pract Gastroenterol Hepatol (2007) 1.00
Impact of comorbidities on clinical outcomes in non-small cell lung cancer patients who are elderly and/or have poor performance status. Crit Rev Oncol Hematol (2009) 0.98
Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients. J Natl Cancer Inst (2012) 0.98
Deep sequencing of the hepatitis B virus in hepatocellular carcinoma patients reveals enriched integration events, structural alterations and sequence variations. Carcinogenesis (2012) 0.98
Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol (2003) 0.98
Cancer trends and incidences in Singapore. Jpn J Clin Oncol (2013) 0.97
Tumor tropism of intravenously injected human-induced pluripotent stem cell-derived neural stem cells and their gene therapy application in a metastatic breast cancer model. Stem Cells (2012) 0.97
MicroRNA-224 targets SMAD family member 4 to promote cell proliferation and negatively influence patient survival. PLoS One (2013) 0.96
Amplification and overexpression of PPFIA1, a putative 11q13 invasion suppressor gene, in head and neck squamous cell carcinoma. Genes Chromosomes Cancer (2008) 0.95
Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer. Mol Cancer Ther (2007) 0.95
Early diagnosis of oral cancer based on the surface plasmon resonance of gold nanoparticles. Int J Nanomedicine (2007) 0.95
Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma. Angiogenesis (2011) 0.93
AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer. Mol Cancer Ther (2009) 0.93
A randomized phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderly. J Thorac Oncol (2007) 0.92
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma. Ann Acad Med Singapore (2013) 0.92
Induced pluripotent stem cell-derived neural stem cells transduced with baculovirus encoding CD40 ligand for immunogene therapy in mouse models of breast cancer. Hum Gene Ther (2014) 0.91
The use of digitized endoscopic imaging of 5-ALA-induced PPIX fluorescence to detect and diagnose oral premalignant and malignant lesions in vivo. Int J Cancer (2004) 0.91
A global partnership in medical education between Duke University and the National University of Singapore. Acad Med (2008) 0.91
Identification of serum monocyte chemoattractant protein-1 and prolactin as potential tumor markers in hepatocellular carcinoma. PLoS One (2013) 0.91
Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma. J Hepatol (2011) 0.90
Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br J Clin Pharmacol (2005) 0.90
Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response. Mol Cancer (2009) 0.90
Expression of EBV latent antigens, mammalian target of rapamycin, and tumor suppression genes in EBV-positive smooth muscle tumors: clinical and therapeutic implications. Clin Cancer Res (2009) 0.90
Prolonged survival following maximal cytoreductive effort for peritoneal metastases from recurrent granulosa cell tumor of the ovary. J Gynecol Oncol (2011) 0.90
Hypericin-photodynamic therapy (PDT) using an alternative treatment regime suitable for multi-fraction PDT. J Photochem Photobiol B (2005) 0.89
Improved formulation of photosensitizer chlorin e6 polyvinylpyrrolidone for fluorescence diagnostic imaging and photodynamic therapy of human cancer. Eur J Pharm Biopharm (2008) 0.88
Inflammatory metastatic carcinoma of the colon: a case report and review of the literature. Tumori (2004) 0.88
Novel photodynamic diagnosis of bladder cancer: ex vivo fluorescence cytology using hypericin. Int J Oncol (2003) 0.87
Immune microenvironment in tumor progression: characteristics and challenges for therapy. J Oncol (2012) 0.87
Anti-angiogenic effects of Hypericin-photodynamic therapy in combination with Celebrex in the treatment of human nasopharyngeal carcinoma. Int J Mol Med (2005) 0.86
2011 Young Surgeon's Award Winner: high endothelial venules: a novel prognostic marker in cancer metastasis and the missing link? Ann Acad Med Singapore (2012) 0.86
Clinical validation of a customized multiple signature microarray for breast cancer. Clin Cancer Res (2008) 0.85
Optimal excitation-emission wavelengths for autofluorescence diagnosis of bladder tumors. Int J Cancer (2003) 0.85
Confocal endomicroscopic imaging of normal and neoplastic human tongue tissue using ALA-induced-PPIX fluorescence: a preliminary study. Oncol Rep (2004) 0.85
Titania coated upconversion nanoparticles for near-infrared light triggered photodynamic therapy. ACS Nano (2015) 0.85
Dynamic contrast-enhanced CT imaging of hepatocellular carcinoma in cirrhosis: feasibility of a prolonged dual-phase imaging protocol with tracer kinetics modeling. Eur Radiol (2009) 0.83
Tobacco: deadly in any form or disguise. Lancet (2006) 0.83
Photolon™ --photosensitization induces apoptosis via ROS-mediated cross-talk between mitochondria and lysosomes. Int J Oncol (2011) 0.83
Targeted therapy in hepatocellular carcinoma. Int J Hepatol (2011) 0.82
Novel proteomic biomarker panel for prediction of aggressive metastatic hepatocellular carcinoma relapse in surgically resectable patients. J Proteome Res (2014) 0.82
The evolving landscape of therapeutic drug development for hepatocellular carcinoma. Contemp Clin Trials (2013) 0.82
Capecitabine with radiation is an effective adjuvant therapy in gastric cancers. World J Gastroenterol (2010) 0.82
Detection of squamous cell carcinomas and pre-cancerous lesions in the oral cavity by quantification of 5-aminolevulinic acid induced fluorescence endoscopic images. Lasers Surg Med (2002) 0.82
The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease. Am J Clin Oncol (2013) 0.82
On-table diagnostic accuracy and the clinical significance of routine exploration in open appendectomies. Asian J Surg (2005) 0.82
Effect of hypericin-mediated photodynamic therapy on the expression of vascular endothelial growth factor in human nasopharyngeal carcinoma. Int J Mol Med (2007) 0.81
Squamous cell carcinoma of the head and neck (HNSCC)--multi-modality treatment and impact on survival. Asian J Surg (2002) 0.81
Investigation into a surface plasmon related heating effect in surface enhanced Raman spectroscopy. Anal Chem (2007) 0.81